Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

University of Electronic Science and Technology of China (UESTC)

Status and phase: Unknown; Phase 2

Conditions: Non-Small-Cell Lung; Thoracic Neoplasms; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Treatments: Drug: Apatinib; Drug: EGFR-TKI

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT03389256

APTN-NSCLC-201712

Details and patient eligibility

About

This phase 2 study is designed to evaluate the safety and activity of apatinib,a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2, in combination with EGFR-TKI in NSCLC with T790M-negative after the failure of EGFR-TKI therapy.

Enrollment: 144 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pathologically confirmed stage IIIB, IV non-squamous non-small cell lung cancer, with measurable lesions (the long axis of tumor lesions ≥ 10mm with CT, the short axis of lymph node lesions ≥ 15mm with CT, the lesions not receive radiotherapy, frozen or other local treatment);
• Patients with slow progression on first-line EGFR TKI(erlotinib / icotinib / gefitinib) treatment;
• No T790M mutation including an assessment from tumor biopsy obtained while on or subsequent to the most recent EGFR TKI therapy;
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2;
• Life expectancy of more than 3 months;
• Adequate bone marrow function: WBC ≥ 3.0 ×10 E+9/L, neutrophil ≥ 1.5 × 10 E+9/L, platelets ≥ 80 × 10E+9/L,Hb ≥ 10.0g/dL;a total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL), a alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤3UNL or ≤5UNL in case of liver metastasis, a creatinine (Cr) of ≤ 1.5 UNL; a creatinine clearance rate ≥ 50ml/min (Cockcroft-Gault);
• Female subjects of child-bearing potential must agree to use contraceptive measures starting 1 week before the administration of the first dose of apatinib until 8 weeks after discontinuing study drug. Male subjects must agree to use contraceptive measures during the study and 8 weeks after last dose of study drug;
• the participants volunteered to join this study should sign the informed consent forms, have better compliance in the follow-up;

Exclusion criteria

• Squamous cell carcinoma (including adenosquamous carcinoma); Small cell lung carcinoma (including small cell carcinoma and non-small cell mixed lung carcinoma);
• Active brain metastases, cancerous meningitis, patients with spinal cord compression;
• Rapid progression of the disease or cancer invades vital organs;
• The distance between the tumor lesion and the large blood vessel is less than 5 mm, or there is a central tumor invading local macrovascular;
• obvious pulmonary cavity or tumor necrosis;
• Uncontrollable high blood pressure;
• Grade Ⅱ or above myocardial ischemia or myocardial infarction or arrhythmia control is not good,Ⅲ ~ Ⅳ grade cardiac insufficiency, or cardiac ultrasonography showed left ventricular ejection fraction (LVEF) <50% according to the NYHA standard;
• Have a history of interstitial lung disease or patients with interstitial lung disease;
• Coagulation abnormalities (INR> 1.5 or PT> ULN + 4s or APTT> 1.5 ULN) with bleeding tendency or undergoing thrombolytic or anticoagulant therapy;
• There was significant hemoptysis within 2 months prior to enrollment, or a daily hemoptysis volume is 2.5 ml or above;
• A clinically significant bleeding symptom or bleeding tendencies such as gastrointestinal bleeding, hemorrhagic gastric ulcer, fecal occult blood ++ and above, or vasculitis that occurred within 3 months prior to enrollment;
• Aneurysm / venous thrombotic events such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism;
• Arterial / venous thrombotic events such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism within 12 months prior to enrollment;
• Hereditary or acquired bleeding and thrombophilia, such as hemophilia, coagulopathy, thrombocytopenia, hypersplenism；
• Long-term unhealed wounds or fractures;
• Major surgery or severe traumatic injury, fracture or ulcer within 4 weeks prior to enrollment;
• Unable to swallow, chronic diarrhea or intestinal obstruction;
• Abdominal fistula, gastrointestinal perforation or abdominal abscess within 6 months prior to enrollment;
• Urinary protein ≥ ++, 24-hour urinary protein ≥ 1.0 g;
• Active infections require antimicrobial treatment;
• ALK gene abnormalities (gene fusion or mutation occurred);
• Pregnant or lactating women, or women unwilling or unable to take effective contraception;

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

144 participants in 2 patient groups

apatinib combine with EGFR-TKI

Experimental group

Description:

Every 4 weeks 1 cycle, evaluated the efficacy and safety once every 2 cycles, treat until disease progression or intolerable toxicity

Treatment:

Drug: EGFR-TKI

Drug: Apatinib

EGFR-TKI

Active Comparator group

Description:

Every 4 weeks 1 cycle, evaluated the efficacy and safety once every 2 cycles, treat until disease progression or intolerable toxicity

Treatment:

Drug: EGFR-TKI